The DISC5 Awards will support exploratory and innovative foundational research led by pairs of interdisciplinary investigators applying a range of technologies and approaches to address fundamental ...

The Alpha Clinics Network is funded and supported by the California Institute for Regenerative Medicine (CIRM). The Network features nine world-class medical centers throughout California with a ...

Each of these facilities will support accelerating and de-risking the path to commercialization for cell and gene therapies, advancing industry standards and quality by design, and building a diverse ...

CIRM is supporting a network of 11 Shared Resources Laboratories (SRLs) for Stem Cell-Based Modeling, an important component of CIRM’s Infrastructure Program designed to address challenges that hinder ...

CIRM applicants and awardees wishing to obtain more information about the CIRM Industry Resource Partners’ hPSC offerings should complete the form below to contact CIRM.

Objetivo de la investigación Comprender los defectos de las células progenitoras alveolares en la diabetes tipo 21 y los genes y vías asociados con ellos permitirá desarrollar enfoques terapéuticos ...

Mucopolysaccharidosis type II (MPS II) is an X-linked recessive inherited disease caused by deficiency of the enzyme iduronate 2-sulfatase (IDS), resulting in lysosomal accumulation of ...

We have made substantial progress in our study and have completed all 5 Aims. We successfully obtained biopsy-derived cells and blood samples from pediatric-onset Crohn’s disease patients that had a ...

During this award, a novel gene editing therapy was further developed and tested. This therapy uses molecular scissors to permanently remove mutations for 50% of Duchenne muscular dystrophy patients, ...

Heart disease is a leading cause of death, but there is no current treatment that can regenerate heart muscle that is lost after heart attack or other cardiac injury. To overcome this, Tenaya has ...

The CLIN1 award provided by CIRM for the preclinical development of QXL138AM supported the successful GMP manufacturing of QXL138AM to provide clinical drug supply required for the first-in-human ...